Here are the 8-K filings from Trevena Inc (TRVN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow TRVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRVN filings page.
Trevena, Inc. entered into an Assignment and Release Agreement under which its lender agreed to terminate and release the company from all obligations under a royalty-based loan agreement, except for indemnification and other obligations that already survive termination under that loan’s existing terms. In return, Trevena agreed to transfer all of its rights, title, and interest in its Chinese License Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. for royalties in the China territory. Trevena will retain only the rights to commercialization milestone payments under that Chinese license.